Impact of the Women's Health Initiative Trial Results on Hormone Replacement Therapy
- 1 April 2004
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (4) , 495-499
- https://doi.org/10.1592/phco.24.5.495.33349
Abstract
To describe the impact of the results of the Women's Health Initiative (WHI) on hormone replacement therapy (HRT) discontinuation rates. Retrospective chart review. University-based family medicine clinic. Ninety-eight postmenopausal women (aged 50-79 yrs) with an intact uterus who were receiving HRT. Two study periods were defined: pre-WHI (July 9, 2001-January 9, 2002) and post-WHI (July 9, 2002-January 9, 2003). Patient demographics and HRT discontinuation or persistence data were collected. Seven women were eligible for only for pre-WHI, 13 only for post-WHI, and 78 were eligible for both groups based on HRT use during both time periods. Forty-two of the 78 women were randomized to the pre-WHI group and 36 to the post-WHI group to yield equal groups of 49 each. No significant demographic differences existed between the groups. Time-to-event analysis revealed an increased probability of HRT discontinuation after WHI versus before WHI (log-rank test, p<0.01). A subset of 85 women taking HRT 1 year before WHI were followed for 18 months. Discontinuation rates were 8% (7 of 85 patients) during the 12 months before WHI and 38% (30 of 78) during the 6 months after WHI, with 80% (24 of 30) of these patients discontinuing within 3 months. Increased HRT discontinuation was temporally associated with release of WHI data, which implies that highly publicized, negative outcomes data can quickly influence pharmacotherapy decisions.Keywords
This publication has 23 references indexed in Scilit:
- The Quality of Health Care Delivered to Adults in the United StatesNew England Journal of Medicine, 2003
- Improving the Quality of Care — Can We Practice What We Preach?New England Journal of Medicine, 2003
- Prescriptions for Estrogen Replacement Therapy in Ontario Before and After Publication of the Women's Health Initiative StudyJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopauseAmerican Journal of Obstetrics and Gynecology, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Postmenopausal Hormone Therapy and MortalityNew England Journal of Medicine, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)Cancer Causes & Control, 1994